| Ytd | -5.52% | |
| 1y | 33.49% |
| Open | 29.26 | Prev Close | 28.37 | Low | 29.01 | High | 29.32 | Mkt Cap | 17.41B |
| Vol | 408.07K | Avg Vol | 1.94M | EPS | 1.39 | P/E | 20.41 | Forward P/E | 17.18 |
| Beta | 0.84 | Short Ratio | 4.95 | Inst. Own | 13.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 26.66 | 200-d Avg | 29.21 | 1yr Est | 36.92 |
GMAB News
Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning fut
Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, back
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituxima
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Co
Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westl
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label
AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met th
Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combin
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase it
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 202
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two st
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial sho
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today
Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the P
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance w
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatilit
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck
Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrade
On Wednesday, 807 companies reached new 52-week lows.
This morning 77 companies reached new 52-week highs.
Stocks That Hit 52-Week Lows On Monday